bluebird bio (BLUE) Competitors $4.97 0.00 (0.00%) As of 06/2/2025 Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock BLUE vs. SOPH, OGI, NLTX, LRMR, INMB, CYBN, VYGR, TLSA, EDIT, and VTYXShould you be buying bluebird bio stock or one of its competitors? The main competitors of bluebird bio include SOPHiA GENETICS (SOPH), Organigram (OGI), Neoleukin Therapeutics (NLTX), Larimar Therapeutics (LRMR), INmune Bio (INMB), Cybin (CYBN), Voyager Therapeutics (VYGR), Tiziana Life Sciences (TLSA), Editas Medicine (EDIT), and Ventyx Biosciences (VTYX). These companies are all part of the "pharmaceutical products" industry. bluebird bio vs. Its Competitors SOPHiA GENETICS Organigram Neoleukin Therapeutics Larimar Therapeutics INmune Bio Cybin Voyager Therapeutics Tiziana Life Sciences Editas Medicine Ventyx Biosciences bluebird bio (NASDAQ:BLUE) and SOPHiA GENETICS (NASDAQ:SOPH) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, profitability, earnings, risk, media sentiment, valuation, community ranking, dividends and analyst recommendations. Does the MarketBeat Community favor BLUE or SOPH? bluebird bio received 1022 more outperform votes than SOPHiA GENETICS when rated by MarketBeat users. However, 70.37% of users gave SOPHiA GENETICS an outperform vote while only 70.34% of users gave bluebird bio an outperform vote. CompanyUnderperformOutperformbluebird bioOutperform Votes104170.34% Underperform Votes43929.66% SOPHiA GENETICSOutperform Votes1970.37% Underperform Votes829.63% Do institutionals and insiders believe in BLUE or SOPH? 87.4% of bluebird bio shares are held by institutional investors. Comparatively, 31.6% of SOPHiA GENETICS shares are held by institutional investors. 1.4% of bluebird bio shares are held by insiders. Comparatively, 4.9% of SOPHiA GENETICS shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth. Is BLUE or SOPH more profitable? SOPHiA GENETICS has a net margin of -98.51% compared to bluebird bio's net margin of -565.74%. SOPHiA GENETICS's return on equity of -63.47% beat bluebird bio's return on equity.Company Net Margins Return on Equity Return on Assets bluebird bio-565.74% -322.46% -53.17% SOPHiA GENETICS -98.51%-63.47%-40.06% Do analysts prefer BLUE or SOPH? bluebird bio currently has a consensus target price of $44.60, indicating a potential upside of 797.38%. SOPHiA GENETICS has a consensus target price of $6.80, indicating a potential upside of 122.95%. Given bluebird bio's higher probable upside, equities analysts clearly believe bluebird bio is more favorable than SOPHiA GENETICS.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score bluebird bio 0 Sell rating(s) 6 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.25SOPHiA GENETICS 0 Sell rating(s) 1 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.75 Does the media favor BLUE or SOPH? In the previous week, bluebird bio's average media sentiment score of 0.00 equaled SOPHiA GENETICS'saverage media sentiment score. Company Overall Sentiment bluebird bio Neutral SOPHiA GENETICS Neutral Which has more risk and volatility, BLUE or SOPH? bluebird bio has a beta of 0.27, meaning that its stock price is 73% less volatile than the S&P 500. Comparatively, SOPHiA GENETICS has a beta of 1, meaning that its stock price has a similar volatility profile to the S&P 500. Which has preferable earnings and valuation, BLUE or SOPH? SOPHiA GENETICS has lower revenue, but higher earnings than bluebird bio. SOPHiA GENETICS is trading at a lower price-to-earnings ratio than bluebird bio, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratiobluebird bio$103.95M0.47-$211.91M-$41.32-0.12SOPHiA GENETICS$65.17M3.12-$62.49M-$1.00-3.05 SummarySOPHiA GENETICS beats bluebird bio on 11 of the 16 factors compared between the two stocks. Get bluebird bio News Delivered to You Automatically Sign up to receive the latest news and ratings for BLUE and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding BLUE and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart BLUE vs. The Competition Export to ExcelMetricbluebird bioBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$48.67M$1.37B$5.37B$8.54BDividend YieldN/A1.04%5.38%4.23%P/E Ratio-0.133.0725.7219.28Price / Sales0.47243.19392.85106.09Price / CashN/A34.7925.4426.73Price / Book0.146.307.885.66Net Income-$211.91M-$75.32M$3.15B$248.36M7 Day PerformanceN/A-2.34%-0.73%0.66%1 Month Performance-0.40%-1.01%3.32%3.66%1 Year Performance-75.64%13.29%41.34%14.80% bluebird bio Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)BLUEbluebird bio2.6196 of 5 stars$4.97flat$44.60+797.4%N/A$48.67M$103.95M-0.13520SOPHSOPHiA GENETICS1.5415 of 5 stars$2.89+0.7%$6.80+135.3%-35.4%$192.73M$67.17M-2.65520Gap UpOGIOrganigram0.5041 of 5 stars$1.43+2.1%N/A-16.1%$191.45M$194.09M-3.76860NLTXNeoleukin TherapeuticsN/A$19.76-3.1%N/A-42.7%$185.70MN/A-6.3590High Trading VolumeLRMRLarimar Therapeutics2.7536 of 5 stars$2.89+0.3%$19.67+580.5%-70.2%$185.04MN/A-2.5130Gap DownINMBINmune Bio2.3248 of 5 stars$8.02+4.2%$22.80+184.3%-16.1%$184.33M$50K-3.6810Gap DownHigh Trading VolumeCYBNCybin1.9683 of 5 stars$8.04-3.7%$86.00+969.7%N/A$184.20MN/A-1.8450VYGRVoyager Therapeutics3.9288 of 5 stars$3.31+0.3%$13.39+304.5%-63.7%$183.16M$66.96M4.66100Gap UpTLSATiziana Life Sciences1.1845 of 5 stars$1.56+0.6%N/A+93.8%$182.28MN/A0.008EDITEditas Medicine3.8097 of 5 stars$2.16+9.6%$5.36+148.3%-58.9%$180.82M$35.84M-0.84230VTYXVentyx Biosciences2.2527 of 5 stars$2.54-0.8%$10.00+293.7%-4.4%$180.75MN/A-1.0830 Related Companies and Tools Related Companies SOPHiA GENETICS Competitors Organigram Competitors Neoleukin Therapeutics Competitors Larimar Therapeutics Competitors INmune Bio Competitors Cybin Competitors Voyager Therapeutics Competitors Tiziana Life Sciences Competitors Editas Medicine Competitors Ventyx Biosciences Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:BLUE) was last updated on 6/24/2025 by MarketBeat.com Staff From Our PartnersThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredF1 Engineering Powers This Electric Marine MotorThe future of marine propulsion has arrived - powered by F-1 grade engineering. In collaboration with McLar...The Tomorrow Investor | SponsoredA grave, grave error.It seems like the world is on fire. Trump’s tariffs are crippling economies worldwide. Canada’s been cri...Porter & Company | Sponsored12 “perfect” stocksJoin the Dream Team and see how we can guarantee stock market wins Credentials are a good thing, especiall...Zacks | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredIs Tesla a buy right now?Wall Street Legend: Why stocks are very likely to crash in Trump's 2nd Year Legendary investor Marc Chaikin...Chaikin Analytics | Sponsored379 passengers walked away from thisWhy Elon Musk Just Invested $51 Million Into Brand New “Miracle Metal” Developed by MIT ScientistsTrue Market Insiders | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding bluebird bio, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share bluebird bio With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy BLUE Stock Free BLUE Stock Alerts